Principal Financial Group Inc. reduced its stake in shares of Anika Therapeutics Inc (NASDAQ:ANIK) by 5.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 115,375 shares of the biotechnology company’s stock after selling 6,706 shares during the period. Principal Financial Group Inc. owned 0.81% of Anika Therapeutics worth $3,878,000 at the end of the most recent quarter.
Several other large investors have also modified their holdings of the company. BlackRock Inc. grew its position in shares of Anika Therapeutics by 3.8% in the third quarter. BlackRock Inc. now owns 2,136,362 shares of the biotechnology company’s stock valued at $90,112,000 after purchasing an additional 78,532 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Anika Therapeutics by 2.0% during the third quarter. Dimensional Fund Advisors LP now owns 997,485 shares of the biotechnology company’s stock worth $42,074,000 after buying an additional 19,916 shares in the last quarter. Vanguard Group Inc grew its position in Anika Therapeutics by 1.0% during the third quarter. Vanguard Group Inc now owns 861,569 shares of the biotechnology company’s stock worth $36,340,000 after buying an additional 8,799 shares in the last quarter. Vanguard Group Inc. grew its position in Anika Therapeutics by 1.0% during the third quarter. Vanguard Group Inc. now owns 861,569 shares of the biotechnology company’s stock worth $36,340,000 after buying an additional 8,799 shares in the last quarter. Finally, AMI Asset Management Corp grew its position in Anika Therapeutics by 1.3% during the fourth quarter. AMI Asset Management Corp now owns 322,062 shares of the biotechnology company’s stock worth $10,825,000 after buying an additional 4,243 shares in the last quarter. 89.82% of the stock is currently owned by institutional investors.
ANIK stock opened at $32.18 on Wednesday. Anika Therapeutics Inc has a twelve month low of $28.54 and a twelve month high of $47.09. The stock has a market cap of $456.62 million, a P/E ratio of 17.49, a PEG ratio of 2.63 and a beta of 1.40.
Anika Therapeutics (NASDAQ:ANIK) last released its earnings results on Thursday, February 21st. The biotechnology company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.32 by $0.22. Anika Therapeutics had a return on equity of 10.54% and a net margin of 17.74%. The business had revenue of $27.00 million for the quarter, compared to the consensus estimate of $26.22 million. During the same period last year, the business earned $0.53 earnings per share. The firm’s revenue for the quarter was down 8.2% compared to the same quarter last year. Analysts anticipate that Anika Therapeutics Inc will post 1.22 EPS for the current year.
A number of equities research analysts recently weighed in on the company. BidaskClub raised Anika Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday. ValuEngine raised Anika Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, April 11th. TheStreet downgraded Anika Therapeutics from a “b-” rating to a “c” rating in a research report on Friday, March 29th. Sidoti set a $35.00 target price on Anika Therapeutics and gave the stock a “hold” rating in a research report on Tuesday, March 5th. Finally, Singular Research reissued a “buy” rating on shares of Anika Therapeutics in a research report on Thursday, February 28th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. Anika Therapeutics currently has a consensus rating of “Hold” and an average target price of $40.00.
In other Anika Therapeutics news, Director Raymond J. Land sold 4,000 shares of Anika Therapeutics stock in a transaction that occurred on Tuesday, February 26th. The stock was sold at an average price of $33.06, for a total transaction of $132,240.00. Following the sale, the director now directly owns 18,992 shares of the company’s stock, valued at $627,875.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Joseph G. Darling acquired 1,000 shares of the firm’s stock in a transaction on Thursday, February 28th. The shares were bought at an average cost of $33.20 per share, for a total transaction of $33,200.00. Following the completion of the acquisition, the chief executive officer now directly owns 22,436 shares of the company’s stock, valued at approximately $744,875.20. The disclosure for this purchase can be found here. 8.08% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.thelincolnianonline.com/2019/04/17/anika-therapeutics-inc-anik-shares-sold-by-principal-financial-group-inc.html.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc, together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology.
Recommended Story: What factors cause inflation to rise?
Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc (NASDAQ:ANIK).
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.